JPMorgan Upgrades Recursion Pharmaceuticals, Inc. (RXRX) on FAP Treatment Prospects [Yahoo! Finance]
Recursion Pharmaceuticals, Inc. - Class A (RXRX)
Company Research
Source: Yahoo! Finance
Recursion Pharmaceuticals (NASDAQ:RXRX) to an Overweight from Neutral and raised the price target to $11 from $10. The upgrade follows promising clinical trials evaluating the MEK 1/2 inhibitor REC-4881 for the treatment of Familial Adenomatous Polyposis (FAP). The TUPELO trial showed that 75% of evaluable patients showed a significant reduction in total polyp burden. “The durable polyp burden reduction demonstrated by REC-4881—especially the sustained effect seen at Week 25, 12 weeks after completing therapy—is highly encouraging for the FAP community,” said Jessica Stout, D.O., Assistant Clinical Professor, University of Utah School of Medicine, and Principal Investigator of the TUPELO study. According to JPMorgan, the company is staring at a tremendous opportunity with REC-4881 with estimated peak sales of more than $1 billion. Additionally, the investment company has touted the company's other candidate drug, REC-617, a CDK7 inhibitor showing early anti-tumor activity in pla
Show less
Read more
Impact Snapshot
Event Time:
RXRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RXRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RXRX alerts
High impacting Recursion Pharmaceuticals, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
RXRX
News
- Recursion Pharmaceuticals, Inc. (RXRX): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
- Is Recursion Pharmaceuticals (RXRX) Pricing In Its AI Drug Discovery Ambitions? [Yahoo! Finance]Yahoo! Finance
- Recursion Pharmaceuticals (RXRX) Stock Drops Despite Market Gains: Important Facts to Note [Yahoo! Finance]Yahoo! Finance
- Recursion Pharmaceuticals (RXRX) Stock Sinks As Market Gains: What You Should Know [Yahoo! Finance]Yahoo! Finance
- Recursion Pharmaceuticals (RXRX) Climbs 6.8% Ahead of Next Week's Business Updates [Yahoo! Finance]Yahoo! Finance
RXRX
Earnings
- 11/5/25 - Beat
RXRX
Sec Filings
- 1/20/26 - Form 144
- 1/12/26 - Form 8-K
- 1/9/26 - Form 3
- RXRX's page on the SEC website